Alcobra, an Israeli drug company developing a non-stimulant ADHD treatment, raised $25 million by offering 3.1 million shares at $8. The company had planned to offer 2.3 million shares at $10 to $12; total proceeds were $25 million, as expected. Alcobra plans to list on the NASDAQ under the symbol ADHD. Aegis Capital acted as the sole bookrunner on the deal.
